Noticias sobre VIH/SIDA
ONUSIDA celebra la adopción de una resolución crucial que reconoce las medidas de reducción del daño en la Comisión de Estupefacientes de las Naciones Unidas
ONUSIDA celebra la adopción hoy de una resolución clave en el 67º periodo de sesiones de la Comisión de Estupefacientes de las Naciones Unidas (CND), en la que se reconoce por primera vez la reducción del daño como parte importante de una respuesta eficaz de salud pública. La resolución anima a los Estados miembros a desarrollar y aplicar medidas de reducción de daños para minimizar las consecuencias adversas para la salud pública y la sociedad del uso no médico de drogas ilícitas. ONUSIDA felicita a la CND y a su Presidente por este hito histórico.
Categorías: VIH/SIDA
Top 5 stories on HIV and women from CROI 2024
The Conference on Retroviruses and Opportunistic Infections (CROI 2024) was held in Denver, US, in March. Here is a roundup of some of the HIV treatment and prevention research focused on women that was presented at the conference.
Categorías: VIH/SIDA
Top 5 HIV PrEP stories from CROI 2024
One of the most important HIV conferences of the year, the Conference on Retroviruses and Opportunistic Infections (CROI 2024), took place earlier this month. Here are some highlights from research on PrEP (regular medication to prevent HIV) presented at CROI.
Categorías: VIH/SIDA
Long-acting injectables can be a good option for people with adherence challenges
Antiretroviral therapy (ART) using cabotegravir and rilpivirine injections monthly or every other month can be an effective HIV treatment option for people who have difficulty maintaining viral suppression on daily pills due to suboptimal adherence, according to studies presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2024).
Categorías: VIH/SIDA
Top 5 stories on co-morbidities affecting people with HIV from CROI 2024
Co-morbidities – other health issues affecting people with HIV – continue to be an important focus of research in the HIV field. Here are some of the top stories on co-morbidities research presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2024).
Categorías: VIH/SIDA
Should event-driven PrEP be an option for women?
HIV pre-exposure prophylaxis (PrEP) could in theory stop the majority of HIV transmissions that still happen, and in some places, including England, is doing so. Yet worldwide, it is still only being used only by a minority of those who could benefit from it.
Categorías: VIH/SIDA
Nearly two million people in sub-Saharan Africa may have advanced HIV disease
Men in sub-Saharan Africa are much more likely to have advanced HIV disease –including large numbers who have a low CD4 count despite taking treatment and being virally suppressed. It remains crucial to monitor CD4 count, according to a World Health Organization (WHO) study of 12 countries presented to the Conference on Retroviruses and Opportunistic Infections by Dr Dominik Stelzle in Denver earlier this month.
Categorías: VIH/SIDA
Top 5 HIV treatment stories from CROI 2024
The Conference on Retroviruses and Opportunistic Infections (CROI 2024) took place this month. Researchers presented work on new and existing HIV treatment options. Here are some of the highlights.
Categorías: VIH/SIDA
ONUSIDA insta a ampliar los servicios basados en pruebas para abordar la transmisión del VIH y la hepatitis viral entre las personas que consumen drogas
En la 67.ª reunión de la Comisión de Narcóticos de las Naciones Unidas que se celebra en Viena, ONUSIDA ha solicitado la ampliación urgente de los servicios para prevenir nuevas infecciones por el VIH y la hepatitis viral entre las personas que consumen drogas. Dirigiéndose a los delegados en su mensaje en vídeo, la directora ejecutiva de ONUSIDA, Winnie Byanyima, elogió a algunos países por hacer progresos en la implementación de programas basados en pruebas, pero pidió una acción más audaz.
Categorías: VIH/SIDA
ONUSIDA insta a ampliar los servicios basados en pruebas para hacer frente a la transmisión del VIH y la hepatitis viral entre los consumidores de drogas
En la 67ª reunión de la Comisión de Estupefacientes de las Naciones Unidas que se celebra en Viena, ONUSIDA ha hecho un llamamiento para que se amplíen urgentemente los servicios de prevención de nuevas infecciones por el VIH y la hepatitis vírica entre los consumidores de drogas. Dirigiéndose a los delegados en su mensaje de vídeo, la Directora Ejecutiva de ONUSIDA, Winnie Byanyima, elogió a algunos países por los progresos realizados en la aplicación de programas basados en pruebas, pero hizo un llamamiento para que se tomen medidas más audaces.
Categorías: VIH/SIDA
Semaglutide improves fatty liver disease and inflammation in people with HIV
Semaglutide, best known as a weight-loss medication, reduced liver fat build-up and appears to lower inflammation in people with HIV and metabolic dysfunction-associated steatotic liver disease (MASLD), according to study results presented last week at the Conference on Retroviruses and Opportunistic Infections (CROI 2024).
Categorías: VIH/SIDA
Women with HIV need tailored advice on statins and heart disease risk
Counselling about heart disease risk and statin use for women with HIV should highlight the similar levels of risk for men and women with HIV when communicating the results of the REPRIEVE study, one of the study’s investigators told the Conference on Retroviruses and Opportunistic Infections (CROI 2024) in Denver last week.
Advice also needs to make women aware of how the symptoms of heart disease differ in women and men.
[GLOSSARY]
Categorías: VIH/SIDA
Progress in reducing new HIV diagnoses much slower for Black men in the US
Lifetime risk of acquiring HIV has decreased for Black gay and bisexual men in the US, from 1 in 2 from 2010 to 2014 to 1 in 3 from 2017 to 2021, according to data presented to the Conference on Retroviruses and Opportunistic Infections (CROI 2024) by researchers from the US Centers for Disease Control and Prevention (CDC) last week.
Categorías: VIH/SIDA
The cornerstone of HIV treatment may be losing some of its power: will dolutegravir resistance become a problem?
A number of presentations at last week’s Conference on Retroviruses and Opportunistic Infections (CROI 2024) looked at whether HIV is starting to develop resistance to dolutegravir, one of the most widely used antiretrovirals in the world.
Categorías: VIH/SIDA
Ultra-long-acting cabotegravir could be taken three times a year for HIV PrEP and treatment
An longer-acting formulation of cabotegravir may offer an HIV pre-exposure prophylaxis (PrEP) and treatment option that could be administered once every four months, according to early study results presented last week at the Conference on Retroviruses and Opportunistic Infections (CROI 2024).
Categorías: VIH/SIDA
HIV medication dolutegravir not linked with increased blood pressure during pregnancy
Dolutegravir did not increase the risk of high blood pressure during pregnancy in a large international study, but mildly raised blood pressure was common in young women with HIV, Professor Risa Hoffman reported on behalf of the IMPAACT 2010 study team at the Conference on Retroviruses and Opportunistic Infections (CROI 2024) in Denver last week.
Categorías: VIH/SIDA
Switch to an integrase inhibitor leads to greater weight during and after the menopause
Switching to an integrase inhibitor around the time of the menopause was associated with accelerated weight gain in women with HIV when compared to pre-menopausal women with HIV, a retrospective cohort study has found.
The study, conducted in the United States, was presented last week at the Conference on Retroviruses and Opportunistic Infections (CROI 2024) in Denver by Dr Rebecca Abelman of University of California San Francisco.
Categorías: VIH/SIDA
Huge increase in PrEP uptake when services offer choice, flexibility <i>and</i> injectable PrEP, African study shows
A programme in rural Kenya and Uganda that has already demonstrated that a dynamic, person-centred HIV prevention intervention results in substantial increases in the numbers of people covered by PrEP or PEP, has now shown the added benefits of offering a choice between PrEP pills and PrEP injections.
Categorías: VIH/SIDA
Far fewer HIV infections in Australian PrEP users – consistent use is key
An impressive 79% reduction in HIV incidence was seen between two directly comparable groups in a whole-population analysis from Australia, presented to the Conference on Retroviruses and Opportunistic Infections (CROI 2024) this week by Dr Nicholas Medland.
People who have received hepatitis C treatment and who were not adherent to PrEP were particularly vulnerable to acquiring HIV within a few years of receiving their first PrEP prescription.
Categorías: VIH/SIDA
Some children who start antiretrovirals very early may control HIV after stopping treatment
A small proportion of children who start HIV treatment within the first two days of life may achieve ongoing viral suppression after stopping antiretrovirals, according to study results presented yesterday at the Conference on Retroviruses and Opportunistic Infections (CROI 2024). While these promising findings hold clues for HIV cure research, such early therapy is out of reach for many, and treatment interruption remains risky without careful monitoring.
Categorías: VIH/SIDA